Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study.

ABSTRACT:

Background

Bevacizumab provides clinical benefit in multiple solid tumours, but is associated with some increase in bleeding risk. Thrombotic events necessitating therapeutic anticoagulation (TA) are common in cancer. This report describes the safety of concurrent bevacizumab and TA in three large placebo-controlled clinical studies.

Methods

Study 1 (metastatic colorectal cancer (mCRC)), study 2 (mCRC), and study 3 (advanced non-small cell lung cancer) were blinded phase III studies. Eligibility criteria excluded patients on TA. Patients on protocol treatment who developed thrombotic events requiring TA were permitted to continue bevacizumab or placebo under specified conditions. Adverse events in patients who received bevacizumab and TA concurrently were assessed using the

SUBMITTER: Leighl NB 

PROVIDER: S-EPMC3049570 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature